creatine has been researched along with Hepatitis C, Chronic in 7 studies
Hepatitis C, Chronic: INFLAMMATION of the LIVER in humans that is caused by HEPATITIS C VIRUS lasting six months or more. Chronic hepatitis C can lead to LIVER CIRRHOSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This elevation is unrelated to hepatic encephalopathy or a history of intravenous drug abuse, and suggests that a biological process underlies the extrahepatic symptoms in chronic HCV infection." | 1.31 | Evidence for a cerebral effect of the hepatitis C virus. ( Allsop, JM; Forton, DM; Foster, GR; Main, J; Taylor-Robinson, SD; Thomas, HC, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bladowska, J | 1 |
| Zimny, A | 1 |
| Knysz, B | 1 |
| Małyszczak, K | 1 |
| Kołtowska, A | 1 |
| Szewczyk, P | 1 |
| Gąsiorowski, J | 1 |
| Furdal, M | 1 |
| Sąsiadek, MJ | 1 |
| Forton, DM | 2 |
| Hamilton, G | 1 |
| Allsop, JM | 2 |
| Grover, VP | 1 |
| Wesnes, K | 1 |
| O'Sullivan, C | 1 |
| Thomas, HC | 2 |
| Taylor-Robinson, SD | 2 |
| Tan, JC | 1 |
| Pattullo, V | 1 |
| McAndrews, MP | 1 |
| Damyanovich, A | 1 |
| Heathcote, EJ | 1 |
| Byrnes, V | 1 |
| Miller, A | 1 |
| Lowry, D | 1 |
| Hill, E | 1 |
| Weinstein, C | 1 |
| Alsop, D | 1 |
| Lenkinski, R | 1 |
| Afdhal, NH | 1 |
| Le Moing, V | 1 |
| Chêne, G | 1 |
| Spire, B | 1 |
| Raffi, F | 1 |
| Leport, C | 1 |
| Main, J | 1 |
| Foster, GR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Study of Cerebral Function in Patients With Chronic Hepatitis C Infection Before and After Pegylated Interferon Alfa-2a and Ribavirin Therapy[NCT00788918] | 100 participants (Actual) | Interventional | 2008-11-30 | Completed | |||
| Personalized Medicine in HCV Infection: Cognitive Impairments and Brain Anomalies in Chronic Hepatitis C Infected Individuals. Characterization and Potential Reversibility With Direct Antiviral Agents.[NCT02745132] | Phase 4 | 80 participants (Anticipated) | Interventional | 2016-06-30 | Not yet recruiting | ||
| A Study of the Cerebral Effect of Pegylated Interferon in Hepatitis C Positive Subjects[NCT00136214] | 22 participants (Actual) | Observational | 2004-03-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
A battery of pen and paper neurocognitive tests where subject means are reported compared to the normative Z score. Data is reported at baseline (T1), week 12 on treatment (T2) and 12 weeks after treatment (week 60, T3). Improvements are increases in the test result compared to baseline as determined against the Z score. tests performed included Hopkins learning trials (HVLT), a measure of of verbal learning and memory and the Roy-Osterrieth Complex figure test (ROCF) which evaluates visio-spatal abilities, memory, planning and working memory. Improvements in the score (increases in value compared, either less negative or more positive to the Z score) shown in the table are reflective of improvements in these neurocognitive parameters. (NCT00136214)
Timeframe: 18 months overall with measures performed at baseline (T1), week 12 (T2) and 12 weeks after end of treatment (T3) with PEG-IFN for 48 weeks which is 60 weeks post baseline and only done in treated group and not controls
| Intervention | Z-score (Mean) | |||||
|---|---|---|---|---|---|---|
| HVLT, Verbal Learning Total, T1 | HVLT, Verbal Learning Total, T2 | HVLT, Verbal Learning Total, T3 | ROCF, T1 | ROCF, T2 | ROCF,T3 | |
| Interferon Treated Group | -1.43 | -0.78 | -0.7 | 0.34 | 0.15 | 0.33 |
| Non-treated Cohort Control | -2.0 | -1.16 | NA | -1.0 | 0.05 | NA |
Evaluation of changes in MR spectroscopy. reductions in ratio of Cho and MI reflect improvements in cerebral inflammation and improvement in cognition. Increases in the NAA ratio are suggestive of improvement in cognitive function. (NCT00136214)
Timeframe: 18 months overall with measures performed at baseline (T1), week 12 (T2) and 12 weeks after end of treatment (T3) with PEG-IFN for 48 weeks which is 60 weeks post baseline
| Intervention | ratio (Mean) | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Basal Ganglia, T1, Cho/Cr | Basal Ganglia,T2, Cho/Cr | Basal Ganglia, T3, Cho/Cr | Basal Ganglia, T1, MI/Cr | Basal Ganglia T2. MI/C | Basal Ganglia T3, MI/C | Frontal Cortex T1, Cho/Cr | Frontal Cortex T2, Cho/Cr | Frontal Cortex T3, Cho/Cr | Basal Ganglia T1, NAA/Cr | Basal Ganglia T2, NAA/Cr | Basal Ganglia T3, NAA/Cr | Frontal Cortex T1,Mi/Cr | Frontal Cortex T2, MI/Cr | Frontal Cortex T3, MI/Cr | Frontal Cortex T1, NAA/Cr | Frontal Cortex T2, NAA/Cr | Frontal Cortex T3, NAA/Cr | DLPFC T1, Cho/Cr | DLPFC T2, Cho/Cr | DLPFC T3, Cho/Cr | DLPFC T1, MI/Cr | DLPFC T2, MI/Cr | DLPFC T3/ MI/Cr | DLPFC T1, NAA/Cr | DLPFC T2, NAA/Cr | DLFPC T3, NAA/Cr | |
| Interferon Treated Group | 0.42 | 0.28 | 0.34 | 0.78 | 0.71 | 0.75 | 0.29 | 0.26 | 0.29 | 1.26 | 1.25 | 1.09 | 0.68 | 0.75 | 0.71 | 1.73 | 1.74 | 1.75 | 0.31 | 0.25 | 0.26 | 0.79 | 0.75 | 0.93 | 1.72 | 1.65 | 1.78 |
| Non-treated Cohort Control | 0.30 | 0.28 | NA | 0.78 | 0.72 | NA | 0.28 | 0.29 | NA | 1.28 | 1.07 | NA | 0.77 | 1.19 | NA | 1.55 | 1.72 | NA | 0.27 | 0.27 | NA | 0.78 | 0.86 | NA | 1.61 | 1.60 | NA |
1 trial available for creatine and Hepatitis C, Chronic
| Article | Year |
|---|---|
Effects of anti-viral therapy and HCV clearance on cerebral metabolism and cognition.
Topics: Adult; Aged; Antiviral Agents; Aspartic Acid; Basal Ganglia; Choline; Cognition; Cognition Disorders | 2012 |
Effects of anti-viral therapy and HCV clearance on cerebral metabolism and cognition.
Topics: Adult; Aged; Antiviral Agents; Aspartic Acid; Basal Ganglia; Choline; Cognition; Cognition Disorders | 2012 |
Effects of anti-viral therapy and HCV clearance on cerebral metabolism and cognition.
Topics: Adult; Aged; Antiviral Agents; Aspartic Acid; Basal Ganglia; Choline; Cognition; Cognition Disorders | 2012 |
Effects of anti-viral therapy and HCV clearance on cerebral metabolism and cognition.
Topics: Adult; Aged; Antiviral Agents; Aspartic Acid; Basal Ganglia; Choline; Cognition; Cognition Disorders | 2012 |
6 other studies available for creatine and Hepatitis C, Chronic
| Article | Year |
|---|---|
Evaluation of early cerebral metabolic, perfusion and microstructural changes in HCV-positive patients: a pilot study.
Topics: Adult; Aspartic Acid; Blood Volume; Brain; Brain Diseases; Case-Control Studies; Cerebrovascular Cir | 2013 |
Cerebral immune activation in chronic hepatitis C infection: a magnetic resonance spectroscopy study.
Topics: Adult; Attention; Brain; Case-Control Studies; Cognition; Creatine; Female; Hepatitis C, Chronic; Hu | 2008 |
Chronic hepatitis C and chronic kidney disease.
Topics: Creatine; Disease Progression; Global Health; Glomerular Filtration Rate; Hepatitis C, Chronic; Huma | 2010 |
Influence of hepatitis C virus on neurocognitive function in patients free from other risk factors: validation from therapeutic outcomes.
Topics: Aspartic Acid; Brain; Cognition Disorders; Cohort Studies; Creatine; Fatigue; Female; Globus Pallidu | 2011 |
[Outcome of HIV-infected patients after 5 years of antiretroviral therapy including a protease inhibitor: the Aproco/Copilote Cohort].
Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Clinical Trials as Topic; Cohort | 2005 |
Evidence for a cerebral effect of the hepatitis C virus.
Topics: Adult; Basal Ganglia; Basal Ganglia Diseases; Biopsy; Brain; Brain Diseases; Choline; Creatine; Fati | 2001 |